SCHEMBL23999396

SCHEMBL23999396

N#Cc1ccc2nccc(Nc3ccc(-c4nc5ccc(Nc6ccncc6)nc5[nH]4)cc3)c2c1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPKAPK2 P49137 2/20 0.52
▸ GAK O14976 1/20 0.46
▸ RIPK2 O43353 1/20 0.46
▸ COQ8A Q8NI60 1/20 0.46
▸ NLK Q9UBE8 1/20 0.46
▸ PKN1 Q16512 1/20 0.46
▸ PKN2 Q16513 1/20 0.46
▸ KDR P35968 11/20 0.44
▸ RAF1 P04049 1/20 0.40
▸ BRAF P15056 1/20 0.40
▸ CSNK1A1 P48729 1/20 0.39
▸ CSNK1D P48730 1/20 0.39
▸ GSK3B P49841 1/20 0.39
▸ CSNK1G2 P78368 1/20 0.39
▸ CCNC P24863 1/20 0.39
▸ CDK8 P49336 1/20 0.39
▸ ALK Q9UM73 1/20 0.39
▸ LRRK2 Q5S007 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24006095 0.91 MAPKAPK2 (0.44) MAPKAPK2GAKRIPK2COQ8ANLK
SCHEMBL30287671 0.91 MAPKAPK2 (0.44) MAPKAPK2GAKRIPK2COQ8ANLK
SCHEMBL24004064 0.88 MAPKAPK2 (0.49) MAPKAPK2GAKRIPK2COQ8ANLK
SCHEMBL30180523 0.88 MAPKAPK2 (0.49) MAPKAPK2GAKRIPK2COQ8ANLK
SCHEMBL23999984 0.86 MAPKAPK2 (0.51) MAPKAPK2GAKRIPK2COQ8ANLK
SCHEMBL23999436 0.86 KDR (0.59) MAPKAPK2GAKRIPK2COQ8ANLK
SCHEMBL23999350 0.86 KDR (0.59) MAPKAPK2GAKRIPK2COQ8ANLK
SCHEMBL23999449 0.85 MAPKAPK2 (0.52) MAPKAPK2GAKRIPK2COQ8ANLK
SCHEMBL23999513 0.85 MAPKAPK2 (0.52) MAPKAPK2GAKRIPK2COQ8ANLK
SCHEMBL24010186 0.83 MAPKAPK2 (0.44) MAPKAPK2GAKRIPK2COQ8ANLK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295114-A1 AKT3 MODULATORS Georgiamune Inc. 2023-09-21 — — US disclosed
US-20230295114-A1 AKT3 MODULATORS Georgiamune Inc. 2023-09-21 — — US disclosed
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 — — US disclosed
WO-2023081854-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2023-05-11 — — WO disclosed
WO-2021226517-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 — — WO disclosed
WO-2021226519-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295114-A1 AKT3 MODULATORS AKT3, AKT2, MTOR MAPKAPK2 151/4885GAK 499/4885RIPK2 1193/4885
US-20230183226-A1 AKT3 MODULATORS AKT3, AKT2, MTOR MAPKAPK2 138/4885GAK 505/4885RIPK2 1209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback